Serum BAFF levels are related to angiogenesis and prognosis in patients with multiple myeloma

被引：39

作者：

Fragioudaki, M. ^{[1
]}

Tsirakis, G. ^{[1
]}

Pappa, C. A. ^{[2
]}

Aristeidou, I. ^{[1
]}

Tsioutis, C. ^{[1
]}

Alegakis, A. ^{[3
]}

Kyriakou, D. S. ^{[4
]}

Stathopoulos, E. N. ^{[5
]}

Alexandrakis, M. G. ^{[1
]}

机构：

[1] Univ Hosp Heraklion, Dept Hematol, Iraklion 71110, Crete, Greece

[2] Venizel Hosp Heraklion, Dept Hematol, Iraklion, Greece

[3] Univ Crete, Sch Med, Iraklion, Greece

[4] Univ Hosp Larisa, Blood Bank, Larisa, Greece

[5] Univ Hosp Heraklion, Dept Pathol, Iraklion 71110, Crete, Greece

来源：

LEUKEMIA RESEARCH | 2012年 / 36卷 / 08期

关键词：

Multiple myeloma; Angiogenesis; Cytokines; BAFF; Prognosis; BONE-MARROW ANGIOGENESIS; B-LYMPHOCYTE STIMULATOR; MALIGNANT PLASMA-CELLS; NECROSIS-FACTOR FAMILY; NF-KAPPA-B; STAGING SYSTEM; MICROVESSEL DENSITY; CLINICAL-FEATURES; ACTIVATING FACTOR; HODGKIN-LYMPHOMA;

D O I：

10.1016/j.leukres.2012.03.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

B-cell activating factor (BAFF) is a B-cell growth factor. We measured its serum levels and correlated them with parameters of disease activity, as serum levels of tumor necrosis factor-alpha and lactate dehydrogenase, bone marrow microvascular density and proliferating cell nuclear antigen expression, in 50 myeloma patients, in 22 of them in plateau phase and in 20 controls. All of them were higher in patients and in advanced disease while reduced in plateau phase. BAFF correlated with all the above markers. Higher BAFF levels predicted a shorter survival, suggesting an important prognostic marker and a possible therapeutic target in myeloma. (C) 2012 Elsevier Ltd. All rights reserved.

引用

页码：1004 / 1008

页数：5

共 50 条

[41] Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients
Pruneri, G
Ponzoni, M
Ferreri, AJM
Decarli, N
Tresoldi, M
Raggi, F
Baldessari, C
Freschi, M
Baldini, L
Goldaniga, M
Neri, A
Carboni, N
Bertolini, F
Viale, G
BRITISH JOURNAL OF HAEMATOLOGY, 2002, 118 (03) : 817 - 820
[42] The Clinical Utility of Serum BAFF Levels in Pregnant Patients with SLE
Sims, Catherine
Eudy, Amanda
Soneji, Samir
Addae-Konadu, Kateena
Gilner, Jennifer
James, Andra
Federspiel, Jerome
Kovalik, Eugene
Lucas, Anika
Neil, Laura
Snyderman, Amanda
Clowse, Megan
ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 848 - 851
[43] Elevated serum levels of APRIL, but not BAFF, in patients with atopic dermatitis
Matsushita, Takashi
Fujimoto, Manabu
Echigo, Takeshi
Matsushita, Yukiyo
Shimada, Yuka
Hasegawa, Minoru
Takehara, Kazuhiko
Sato, Shinichi
EXPERIMENTAL DERMATOLOGY, 2008, 17 (03) : 197 - 202
[44] Serum BAFF and APRIL levels in Indian patients with Takayasu arteritis
Zanwar, Abhishek
Jain, Avinash
Gupta, Latika
Chaurasia, Smirti
Kumar, Sandeep
Misra, Durga Prasanna
Misra, Ramnath
CLINICAL RHEUMATOLOGY, 2018, 37 (12) : 3439 - 3442
[45] Angiogenesis in multiple myeloma
Sezer, O
Niemöller, K
Jakob, C
Heider, U
LEUKEMIA RESEARCH, 2002, 26 (07) : 701 - 702
[46] Angiogenesis in multiple myeloma
Rajkumar, SV
Greipp, PR
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (03) : 565 - 565
[47] Angiogenesis in multiple myeloma
Jakob, Christian
Sterz, Jan
Zavrski, Ivana
Heider, Ulrike
Kleeberg, Lorenz
Fleissner, Claudia
Kaiser, Martin
Sezer, Orhan
EUROPEAN JOURNAL OF CANCER, 2006, 42 (11) : 1581 - 1590
[48] Angiogenesis in multiple myeloma
Vacca, A
Minischetti, M
Pellegrino, A
Dammacco, F
RECENT ADVANCES IN GERIATRICS, 1998, : 227 - 238
[49] Angiogenesis in multiple myeloma
Rajkumar, SV
Kyle, RA
SEMINARS IN ONCOLOGY, 2001, 28 (06) : 560 - 564
[50] Angiogenesis and Multiple Myeloma
Giuliani, Nicola
Storti, Paola
Bolzoni, Marina
Palma, Benedetta Dalla
Bonomini, Sabrina
CANCER MICROENVIRONMENT, 2011, 4 (03) : 325 - 337

← 1 2 3 4 5 →